Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurane, S.
Right arrow Articles by Chang, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurane, S.
Right arrow Articles by Chang, A. E.

Annals of Surgical Oncology, Vol 4, Issue 7 579-585, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Cytokines as an adjuvant to tumor vaccines: efficacy of local methods of delivery

S. Kurane, M. T. Arca, A. Aruga, R. A. Krinock, J. C. Krauss and A. E. Chang
Division of Surgical Oncology, University of Michigan, Ann Arbor, USA.

BACKGROUND: We examined alternative methods of delivering cytokines as an adjunct for priming lymph node (LN) cells draining sites of vaccine inoculation for the purpose of generating immune cells for adoptive immunotherapy. METHODS: Using syngeneic murine tumors we examined the ability of IL-2, IL-4, or GM-CSF delivered locally to a site of tumor inoculum to induce antitumor reactive draining LN cells. Mice were inoculated subcutaneously with tumor cells transduced to secrete cytokine; tumor cells admixed with fibroblasts transduced to secrete cytokine; or intralesional inoculation of cytokine in established tumor to induce sensitized LN cells capable of mediating tumor regression in adoptive transfer. RESULTS: Both IL-4 and GM-CSF cytokines were effective in enhancing the antitumor reactivity of vaccine-primed LN cells compared to IL-2, which was ineffective. The local delivery of GM-CSF by autocrine or paracrine secretion of genetically engineered cells, as well as direct intratumoral delivery was capable of upregulating LN sensitization compared to systemic administration, which did not. CONCLUSIONS: The local delivery of GM-CSF as an adjuvant for tumor vaccination can be accomplished by various methods, including direct injection, which avoids the need for gene transfer.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. W. Hodge, M. Chakraborty, C. Kudo-Saito, C. T. Garnett, and J. Schlom
Multiple Costimulatory Modalities Enhance CTL Avidity
J. Immunol., May 15, 2005; 174(10): 5994 - 6004.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Driessens, M. Hamdane, V. Cool, T. Velu, and C. Bruyns
Highly Successful Therapeutic Vaccinations Combining Dendritic Cells and Tumor Cells Secreting Granulocyte Macrophage Colony-stimulating Factor
Cancer Res., November 15, 2004; 64(22): 8435 - 8442.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. G. McNeel, K. Schiffman, and M. L. Disis
Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor
Blood, April 15, 1999; 93(8): 2653 - 2659.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society of Surgical Oncology.